Radiopaque resorbable inferior vena cava filter (IVCF) were developed to offer a less expensive alternative to assessing filter integrity in preventing pulmonary embolism for the recommended prophylactic period and then simply vanishes without intervention. In this study, we determined the efficacy of gold nanoparticle (AuNP)-infused poly-p-dioxanone (PPDO) as an IVCF in a swine model. Infusion into PPDO loaded 1.14±0.08 % AuNP by weight as determined by elemental analysis. The infusion did not alter PPDO's mechanical strength nor crystallinity (Kruskal−Wallis one-way ANOVA, p<0.05). There was no cytotoxicity observed (one-way ANOVA, p<0.05) when tested against RF24 and MRC5 cells. Gold content in PPDO was maintained at ~2000 ppm during the 6-week incubation in PBS at 37 o C.
INTRODUCTION
An inferior vena cava filter (IVCF) is deployed in patients who are contradicted with anticoagulant agents to prevent pulmonary embolism [1, 2] . The intended dwell time of a temporary IVCF is 7 to 35 days [3] . These IVCF is to be surgically retrieved once the risk of thromboembolic disease is reduced to prevent filter fracture and perforation due to prolonged use. However, the rate of temporary IVCF retrieval is less than 60%, and the prolonged IVCF dwell time presents a challenge to successful retrieval and life-threatening complications including vessel puncture and IVCF migration. Thus, an absorbable IVCF made from poly-p-dioxanone (PPDO) was developed. PPDO has a favorable degradation profile that can ensure the mechanical strength and integrity of the ICVF with in the intended dwell time, but it will degrade after the intended use and avoid the necessity of another surgical retrieval procedure. Therefore, PPDO-based IVCF could enhance the safety and decrease medical cost while maintaining the efficacy of the IVCF.
However, PPDO is radiolucent and cannot be monitored under conventional imaging modalities, such as X-ray and computed tomography (CT). Thus, the purpose of our research is to develop the first totally absorbable, radiopaque IVCF, whose position and integrity can be easily monitored under X-ray and CT. The clinical implication is to avoid fatal complications associated with failure of retrieval of temporary IVCF. Our previous research has successfully demonstrated the feasibility of radiopacity enhancement by infusing iodine and gold nanoparticles (AuNPs) into PPDO [4, 5] . Our current research continues to investigate the enhanced material discrimination of AuNPs compared to iodine on dual energy CT (DECT) and the impact of AuNP infusion on in vivo imaging and behavior of PPDO IVCF.
MATERIALS & METHODS
Four nanometer AuNPs were synthesized, characterized and infused into PPDO. The ultraviolet-visible (UV-Vis) profile of AuNPs was monitored on a Cary 60 UV-Vis spectrophotometer (Agilent Technologies, Santa Clara, CA).
Particle size was determined on a JEOL 1230 high contrast transmission electron microscope (TEM; JEOL USA, Inc., The radiopacity and mechanical strength of AuNP-PPDO IVCF were evaluated in swine model. Autologous thrombi were introduced one week after the deployment. The radiopacity and ability to capture thrombi was evaluated by CT and compared with uncoated PPDO IVCF. Autopsy was performed to evaluate in vivo toxicity and filter endothelialization.
RESULTS AND DISCUSSION
Gold nanoparticles that were synthesized had an average diameter of 4 nm as shown in the TEM ( Figure 1A ). It has a characteristic absorption peak at 520 nm as shown in the UV-vis absorption profile ( Figure 1B Material discrimination between gold and iodine on DECT was performed to evaluate the ability to differentiate AuNP-PPDO IVCF in the presence of iodine based contrast agent when the filter is deployed in vivo. The prediction of correlation between Hounsfield Unit (HU) value and AuNP and iodine concentrations was studied to evaluate the feasibility of monitoring the integrity of the AuNP-PPDO IVCF from DECT HU readings. AuNP concentration needed to be greater than 0.5 mg/ml at 70 keV for visualization (contrast-to-noise ratio >2). Material discrimination between gold and iodine gave good prediction of correlation between HU value and AuNP and iodine concentrations except for very low AuNP (0-1 mg/mL) ( Figure 4 ).
The radiopacity of the AuNP-PPDO IVCF was evaluated on micro-CT in comparison with an uncoated control PPDO-IVCF ( Figure 5 ). Results in Figure 5 show that there is an increased signal with AuNP-coated IVCF compared to the uncoated one. This clearly demonstrates the enhanced radiopacity of the nanoparticle-coated IVCF that could help us in monitoring the position and integrity during and after the deployment of the filters.
As a proof-of-concept, two pigs were deployed with IVCFs, one with AuNP-PPDO and the other without coating. According to a pilot study performed on PPDO ICVF, endothelialization of the stent portion should occur within two weeks after the deployment [3] . Thus, autopsy was performed at two weeks post deployment to evaluate the entothelialization. Figure 8A shows PPDO ICVF at 19 days post deployment from our previously published data [3] .
The stent had been endothelialized into the vessel wall, and the introduced clot was still captured in the filter. Figure   8B shows that the stent of the AuNP-PPDO IVCF was also endothelialized onto the IVC wall two weeks post deployment, and no sign of filter migration was observed. The introduced clot was also still trapped within the AuNP-PPDO filter. Thus AuNP infusion did not affect the endothelialization process of the PPDO ICVF or its ability to capture and trap circulation clot. Figure 9 shows the H&E staining of the IVC containing the uncoated PPDO IVCF ( Figure 9A ) and AuNP-PPDO IVCF ( Figure 9B ). The oval spaces in Figure 9A and 9B are the endothelialized PPDO fibers. The structure of the IVC containing AuNP-PPDO IVCF is similar to that containing the uncoated PPDO IVCF, and no toxicity was observed.
This result concurs with the in vitro cytotoxicity study that AuNP-PPDO IVCF are biocompatible.
CONCLUSION
We successfully developed a radiopaque, biocompatible and robust AuNP-infused PPDO IVCF. The efficacy of a novel radiopaque nanoparticle-based resorbable IVCF was evaluated both in vitro and in vivo. Preliminary pig study clearly showed the visibility of AuNP-PPDO IVCF in conventional clinical CT, even in the presence of clot and iodine contrast agent, which indicates the ability to differentiate AuNP-PPDO IVCF from iodine contrast agent and clot.
Endothelialization and function of the IVCF was maintained. This suggests the efficacy of this novel, radiopaque, absorbable IVC filter for monitoring its position and integrity over time, thus increasing the safety and efficacy of deep vein thrombosis treatment.
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